Bio-Rad Labs (BIO) Provides Outlook Through 2023
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Bio-Rad Provides Outlook Through 2023
December 10, 2020 5:33 PM ESTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook through 2023, which shows the companys commitment to continued organic growth, continued margin expansion, and its efforts on sustainability measures.
Since our last Investor Day in 2017, Bio-Rad has executed on the key metrics that were laid out and this has translated into delivering significant shareholder value, said Norman Schwartz, Bio-Rad President and Chief Executive Officer. We continue our efforts to balance our investment in innovation with our continued operating discipline. We believe... More
